CORPORATE MEDIA RELEASE
NORGINE TO PRESENT DATA FOR PLENVU® AND XIFAXAN® AT THE UNITED EUROPEAN GASTROENTEROLOGY WEEK (UEG)
AMSTERDAM. The Netherlands. 19 October 2018. 07:00 AM BST / 08:00 AM CET. Norgine B.V., a leading European specialist pharma company will present data at the UEG Week Vienna, October 20 – 24, 2018. Data include:
PLENVU® related posters
XIFAXAN® 550mg (rifaximin) related posters
Notes to Editors:
About PLENVU®
In Europe, PLENVU® is indicated in adults for bowel cleansing prior to any procedure requiring a clean bowel.[ii]
PLENVU is a trademark of the Norgine group of companies.
About XIFAXAN® 550mg
XIFAXAN® (rifaximin) 550mg is indicated for the reduction in recurrence of episodes of overt hepatic encephalopathy in patients ≥ 18 years of age.[iii]
Norgine currently holds marketing rights for rifaximin–α (XIFAXAN® 550mg, also known as TARGAXAN® 550mg in the UK and Belgium) in Australia, Belgium, Denmark, Finland, Germany, Luxembourg, Netherlands, New Zealand, Norway, Republic of Ireland, Sweden and United Kingdom.
XIFAXAN and TARGAXAN are under license from Alfasigma S.p.A.
XIFAXAN and TARGAXAN are registered trademarks of the Alfasigma group of companies, licensed to the Norgine group of companies.
About Norgine
Norgine is a leading European specialist pharmaceutical company with a direct commercial presence in all major European markets. In 2017, Norgine’s total net product sales were EUR 345 million, up 17 per cent.
Norgine employs over 1,000 people across its commercial, development and manufacturing operations and manages all aspects of product development, production, marketing, sale and supply.
Norgine specialises in gastroenterology, hepatology, cancer and supportive care.
Norgine is headquartered in the Netherlands.
For more information, please visit www.norgine.com
In 2012, Norgine established a complementary business Norgine Ventures, supporting innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com.
NORGINE and the sail logo are trademarks of the Norgine group of companies.
Media Contacts:
Isabelle Jouin, T: +44 (0)1895 826237
Follow us @norgine
[i] Repici A., Amlani B., Uebel P., Schreiber S. Superior high-quality colon cleansing with 1L NER1006 versus sodium picosulfate + magnesium citrate, 2L polyethylene glycol + ascorbate, or oral sulfate solution: Post hoc pooled analysis of three randomised phase 3 clinical trials. #P0159. Monday 22 October. 12:30 – 13:30 CET. UEGW.
[ii] PLENVU. SmPC. https://www.medicines.org.uk/emc/product/8578/smpc. October 2017
[iii] XIFAXAN/TARGAXAN 550mg. SmPC. https://www.medicines.org.uk/emc/product/2976/smpc. October 2016